Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0DFXLU
ADC Name
RGCLN18.2-D07-Val-Cit-PAB-MMAE
Synonyms
RGCLN18.2 D07 Val Cit PAB MMAE
   Click to Show/Hide
Organization
RemeGen Co., Ltd.
Drug Status
Investigative
Indication
In total 2 Indication(s)
Gastric cancer [ICD11:2B72]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
Drug-to-Antibody Ratio
3.84
Structure
Antibody Name
RGCLN18.2
  Antibody Info 
Antigen Name
Claudin-18.2 (CLDN18.2)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
D07-Val-Cit-PABC
  Linker Info 
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
4.94
ng/mL
NCI-N87 cells
Gastric tubular adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 4.94 ng/mL Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
References
Ref 1 Anti-claudin 18.2 antibody and antibody-drug conjugate thereof; 2022-11-17.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.